COVID-19 vaccine being administered by GP Source: Shutterstock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Ireland is the latest country to temporarily suspend the use of AstraZeneca’s COVID-19 vaccine, amid a recent bout of potentially related blood clotting incidents
  • Several patients across Europe have suffered fatal blood clots after being immunised with the COVID-19 vaccine
  • The medicines watchdog in Europe is looking into whether the incidents are linked to the inoculation, though no link has been established to date
  • The drugmaker also argues the blood clot incidents are unrelated and there is no evidence to suggest its vaccine increases the risk of clotting
  • The AstraZeneca jab is the main COVID-19 vaccine being rolled out in many areas, including in Australia

Ireland is the latest country to temporarily suspend the use of AstraZeneca’s COVID-19 vaccine, amid a recent bout of potentially related blood clotting incidents.

The Irish Republic has joined Norway, Italy, Austria, Iceland, Denmark and several other nations in temporarily suspended the rollout of the inoculation.

It follows several patients in Europe presenting with blood clots, which in several cases resulted in deaths.

Several of the countries have launched their own investigation, while the European medicine watchdog has also launched an inquiry into any links between the vaccine and clots.

But, at this stage the European Medicines Agency argues the vaccine is still safe for use with no link between blood clotting and the jab established to date.

The EMA also said the benefits of being immunised far outweigh the risks, with COVID-19 once again flaring up in Europe.

“There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine,” the regulator said in a statement.

“The position of EMA’s safety committee is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing,” it added.

In addition to the regulator’s statement supporting the vaccine, drugmaker AstraZeneca has also stated that there’s no evidence supporting a link between the jab and blood clotting.

“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and U.K. with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the drugmaker said.

AstraZeneca’s vaccine is a major part of numerous vaccination efforts across the globe and is currently being rolled out across Australia.

However, Prime Minister Scott Morrison said the vaccine had been widely tested, including by Australian authorities, and is still safe to be administered.

“I trust our Therapeutic Goods Administration and the advice that they give me,” the PM said when questioned about the blood clot investigation last week.

More From The Market Online

Bullock: Hold call doesn’t rule out further tightening, if that’s required to beat inflation

Michele Bullock has made it very clear that the Reserve Bank is still strongly considering more rate hikes, especially if it’s the only

Reserve Bank holds rates at 4.35% as inflation battle drags on

The Reserve Bank has left the cash rate unchanged at 4.35%, warning inflation remains too high…
Global trade disruption concept with container ships blocked from entering or exiting the Strait of Hormuz. Maritime blockade and geopolitical tension affecting international supply chain and shipping routes.

Markets rally, ASX surges as US-Iran strike preliminary deal to reopen Strait of Hormuz

Australian shares rallied after the US and Iran confirmed a landmark ceasefire agreement, lifting miners, banks…
Close-up view of erupting molten lava, showcasing the intense heat and dynamic nature of volcanic activity.

Records up top, energy melt down, all eyes back on rech

Records on top. Regime turn underneath. Three U.S. indices closed at record highs into a holiday-shortened week. The Philadelphia Semiconductor Index ripped +5.53%...